Abstract 73P
Background
Tumor infiltration by nerves and axial bone metastases often occur in prostate cancer (PCa) patients, however the mechanisms and the link between these processes are not well understood. Here, we report a PCa mouse model, which recapitulates this cancer route of spreading and correlates with radiological images from PCa patients.
Methods
The human androgen-independent PC3-ML cell line with reported bone metastasis potential was orthotopically injected into the prostate of SCID/Bg mice to observe the natural history of cancer spread instead of commonly used intratibial or intracardiac injections. The process of primary and secondary tumor development was monitored by magnetic resonance imaging (MRI). The tissues were collected and immunostained for neuronal markers, neurofilament (NF), and tyrosine hydroxylase (TH), as well as prostate cancer cell marker, pan-cytokeratin, and a vascular marker, CD31. Additionally, clinical cases of patients with representative MRI images of bone metastases and PNI were selected.
Results
The mice MRI revealed the presence of primary prostate tumor with secondary tumors located mostly along the lumbar spinal cord and pelvis, which led to secondary bone infiltration. The histopathological analysis confirmed the presence of PCa cells along the spine with its infiltration. The PCa cells created clusters, which spread along the small, NF-positive nerve fibers that were directed into the bone area. We ruled out the retrograde vessel infiltration by CD31 immunostaining. The clinical relevance of our model was confirmed by the radiological presentation of human PCa cases: 1) a patient with castration-sensitive PCa, with oligometastatic disease (one sacrum metastasis) and infiltration of neurovascular bundle; 2) a patient with castration-resistant PCa with PNI and a relapse in the ilium, who subsequently developed perispinal metastases along the lumbar plexus and spine.
Conclusions
Altogether, the results of our study suggest that PNI may be responsible for the initial PCa dissemination to bone. MRI imaging has adequate sensitivity to detect the nerve infiltration, however it is not commonly used in disseminated PCa patients. Consequently, the number of cases with spine infiltration and bone metastases may be underreported.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Georgetown University Medical Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09